All In Biotech

NDA 050767 · Pfizer

Cleocin

Clindamycin Phosphate · Vaginal

Last checked: Nov 19, 2026Latest source record: Jul 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Aug 13, 1999

Approved uses

1

Original approval plus efficacy supplements

Registered trials

274

66 Phase 3, 28 recruiting

FAERS reports

4,923

2,973 serious, 353 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 9, 2026.

INDICATIONS AND USAGE CLEOCIN Vaginal Ovules are indicated for 3-day treatment of bacterial vaginosis in non-pregnant women. There are no adequate and well-controlled studies of CLEOCIN Vaginal Ovules in pregnant women. NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis , Neisseria gonorrhoeae , Candida albicans , and herpes simplex virus, should be ruled out.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CLEOCIN · CLINDAMYCIN PHOSPHATE 100MG · SUPPOSITORY, VAGINAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.

All 274 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity554
  • drug ineffective431
  • rash366
  • diarrhoea320
  • nausea281
  • off label use263
  • pain251
  • fatigue245
  • pruritus207
  • dyspnoea185
  • headache173
  • pyrexia162

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200439
200590
200682
200723
200842
200984
2010184
2011110
2012136
2013188
2014185
2015240
2016401
2017280
2018377
2019366
2020283
2021231
2022318
2023334
2024316
2025336
2026276

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cleocin (Clindamycin Phosphate)

2024 spending

$120K

Beneficiaries

374

479 claims

Per beneficiary

$320

$57.82 per unit

View as table
YearSpending
2020$201,437
2021$186,964
2022$165,478
2023$166,113
2024$119,524

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,209 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.